A Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Recombinant Human Hyaluronidase PH20 Administered Intravenously in Healthy Volunteers

A Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Recombinant Human Hyaluronidase PH20 Administered Intravenously in Healthy Volunteers

ABSTRACT: Background: Recombinant human hyaluronidase PH20 (rHuPH20) is used in subcutaneous formulations (eg, RITUXAN HYCELA [rituximab and hyaluronidase human], HERCEPTIN HYLECTA [trastuzumab and hyaluronidase-oysk], PHESGO [pertuzumab/trastuzumab/hyaluronidase-zzxf], and Darzalex FASPRO [daratumu...

Full description

Saved in:
Bibliographic Details
Main Authors: Marie A. Printz, BA (Author), Samuel S. Dychter, MD (Author), Emanuel P. DeNoia, MD (Author), Rena Harrigan, MPH (Author), Barry J. Sugarman, PhD (Author), Monica Zepeda, PhD (Author), Jennifer Souratha, BSc (Author), David W. Kang, BSc (Author), Daniel C. Maneval, PhD (Author)
Format: Book
Published: Elsevier, 2020-01-01T00:00:00Z.
Subjects:
article
Online Access:Connect to this object online.
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

Connect to this object online.

3rd Floor Main Library

Holdings details from 3rd Floor Main Library
Call Number: A1234.567
Copy 1 Available

Similar Items